Argentina’s Treasury filed a motion in a New York federal court on January 28 2026 to suspend the discovery phase of the U.S. nationalization case involving YPF Sociedad Anónima. The motion argues that the discovery requests are illegitimate, intrusive, and designed to harass the Republic into settling or to force Argentina into contempt of court.
The lawsuit stems from Argentina’s 2012 expropriation of a controlling stake in YPF from Spain’s Repsol. In 2023 a New York judge ordered Argentina to pay $16 billion in damages to litigation funders Burford Capital and Eton Capital for failing to make a mandatory public takeover bid to minority shareholders. The discovery process is now a battleground for identifying state assets that could be used to satisfy that judgment, including the Central Bank’s gold reserves.
Argentina’s legal team contends that it has already provided sufficient information and that further requests are excessive. The motion seeks to halt additional subpoenas and interrogatories, arguing that the discovery is being used to locate assets rather than to uncover evidence. The U.S. Department of Justice has filed an amicus brief supporting Argentina’s sovereign‑immunity position, underscoring the high stakes of the litigation.
For YPF, the motion signals a shift in the legal strategy that could delay or limit the court’s ability to compel disclosure of the company’s assets. While YPF’s own stance is not publicly disclosed, the filing may affect the company’s operational flexibility and its ability to negotiate settlements or restructure its obligations under the judgment. The outcome of this motion could influence the broader trajectory of the case, potentially preserving Argentina’s control over YPF’s assets and limiting the reach of the $16 billion judgment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.